PSMA617-miR-34a

Overview: 

Prostate-specific membrane antigen (PSMA)-targeted miRNA with the ability to escape the endosome to treat prostate cancer.  Current lead molecule from the PSMA617-mIR platform.


Status: 


Purdue Faculty: 

Dr. Andrea Kasinski

Dr. Philip Low


Development Partner: 

LigamiR Therapeutics


Research Articles: 

Enhancing microRNA activity through increased endosomal release mediated by nigericin

New mechanism for release of endosomal contents: osmotic lysis via nigericin-mediated K+/H+ exchange